Products
-
- BBB DamageCell Death and ApoptosisNeuroinflammationNeuronal Damage and RepairOxidative StressVascular Mechanisms
- 3D BBB Models
- Organ-on-a-Chip BBB ModelsTranswell Models3D BBB Models Culture Substrate
- 3D HydrogelsCollagensAnmial BBB ModelsCell Lines for BBB Modeling
- Immortalized CellsPrimary CellsStem Cells
A3AR covalent antagonist (AC138)
Cat.#: ASSD-138
Specifications
Description A3AR covalent antagonist.Binds irreversibly. Apparent pKi values at A3ARs are 6.9 and 8.0 (after 4h), where a Ki shift indicates a covalent mode of action. Size 50 μg Chemical Name 4-[3-(8-Methoxy-2,4-dioxo-3-propylpurino[7,8-a]pyridin-1-yl)propylcarbamoyl]benzenesulfonyl fluoride Molecule Weight 517.5 Molecular formula C23H24FN5O6S PubChem identifier 155513958 Purity >95% Solubility Soluble in DMSO Storage Store at -20° C Shipping Shipped at 4°C Citation Guidance If you use our product in a scientific publication, please cite it as "Ace Therapeutics Cat.#". Click here to submit your paper's PubMed ID (PMID) to receive rewards. Related Products
Cat.# Name Size Price ASSD-140 A2B covalent ligand (AC140) 50 μg inquiry ASSD-189 7-Hydroxycoumarin-3-carboxylic acid (AC189) 100 mg inquiry ASSD-209 Tetramethylrhodamine isothiocyanate Isomer R (AC209) 5 mg, 10 mg inquiry ASSD-130 Calcein-AM (AC130) 1 mg inquiry ASSD-113 Thionin acetate salt (AC113) 5 g inquiry ASSD-203 Bis(2,2′-bipyridine)-4,4′-dicarboxybipyridine-ruthenium di(N-succinimidyl ester) bis(hexafluorophosphate) (AC203) 5 mg inquiry ASSD-210 7-Amino-4-methyl-3-coumarinacetic acid N-succinimidyl ester (AC210) 5 mg inquiry ASSD-221 Antifade Fluorescence Mounting Medium with DAPI (hard set) (AC221) 10 mL inquiry ASSD-205 Acridinium C2 NHS Ester (AC205) 5 mg, 10 mg inquiry ASSD-135 JC-1 (AC135) 5 mg inquiry All of our products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.
0Inquiry Basket